UBS downgraded Xylem (XYL) to Neutral from Buy with a price target of $132, down from $152. The firm sees near term project delay risks impacting the company’s organic growth. This makes a return to higher growth in 2026 less certain, the analyst tells investors in a research note. Following “negative peer reporting,” UBS reduced its 2026 organic growth estimate for Xylem to 1%.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XYL: